## Tori N Yamamoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8122094/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature, 2021, 597, 544-548.	13.7	94
2	Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nature Biotechnology, 2020, 38, 1174-1183.	9.4	251
3	Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. Cancer Cell, 2020, 37, 818-833.e9.	7.7	96
4	Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells. Journal of Experimental Medicine, 2019, 216, 2619-2634.	4.2	51
5	T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science, 2019, 363, .	6.0	355
6	Developing neoantigen-targeted T cell–based treatments for solid tumors. Nature Medicine, 2019, 25, 1488-1499.	15.2	173
7	T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. Journal of Clinical Investigation, 2019, 129, 1551-1565.	3.9	108
8	Identification of essential genes for cancer immunotherapy. Nature, 2017, 548, 537-542.	13.7	668
9	Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy. Journal of Clinical Investigation, 2015, 126, 318-334.	3.9	193